biomarkers – Medxy AI

Plasma Biomarkers for Neocortical Tau Burden

By MedXY 08/15/2026

A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.

Gastroenterology news

New Insights into Artificial Sweeteners and Emulsifiers in Crohn’s Disease: Biomarkers and Metabolic Mechanisms from the ENIGMA Study

By MedXY 08/14/2026

The ENIGMA study reveals altered metabolism of the emulsifier polysorbate-80 and elevated artificial sweeteners in Crohn's disease, linking these dietary additives to disease activity and potential biomarker development.

Clinical Updates Neurology news Rheumatology

Serum Glial Fibrillary Acidic Protein Dynamics in Multiple Sclerosis: Biomarker Insights into Disease Progression and Therapeutic Response

By MedXY 08/04/2026

Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.

Critical Care Nephrology news

STARDaki: Standardizing How We Report Acute Kidney Injury Biomarker Studies

By MedXY 07/30/2026

An expert consensus (STARDaki) extends STARD to improve reporting of diagnostic test accuracy studies for acute kidney injury (AKI), specifying patient selection, reference standards, timing, assay details and test-retest reliability.

Clinical Updates news Ophthalmology

Tomographic Predictors of Foveal Versus Extrafoveal Atrophy Onset in Intermediate Age-Related Macular Degeneration: Clinical Implications and Biomarker Insights

By MedXY 07/13/2026

Distinct baseline foveal tomographic lesions predict foveal-first versus extrafoveal-first cRORA onset in iAMD. Hyperreflective foci and lesion type inform risk stratification and timing of atrophic progression relevant for emerging dry AMD therapies.

news Oncology Otorhinolaryngology

Advancing Early Detection of Nasopharyngeal Carcinoma: Evaluating the Novel Anti-BNLF2b Antibody Test

By MedXY 07/11/2026

This article critically appraises a multicenter study validating the Anti-BNLF2b antibody (P85-Ab) assay, highlighting its superior sensitivity and specificity for early nasopharyngeal carcinoma detection compared to established EBV-based biomarkers.

Diabetes & Endocrinology General Surgery news

Plasma Oxytocin as a Superior Preoperative Biomarker for Predicting Transient Postoperative Arginine Vasopressin Deficiency Following Transsphenoidal Pituitary Surgery

By MedXY 07/10/2026

This study identifies plasma oxytocin as a superior preoperative biomarker compared to copeptin for early prediction of transient arginine vasopressin deficiency after transsphenoidal pituitary surgery, aiding in risk stratification and postoperative management.

Clinical Updates news

Integrated Intraocular and Plasma Proteomics Identify Neurofilament Light Chain as a Conserved Biomarker for Diabetic Retinopathy Progression: A Multi-Fluid Biopsy Perspective

By MedXY 07/01/2026

This review synthesizes evidence on neurofilament light chain (NFL) as a minimally invasive plasma biomarker predictive of diabetic retinopathy progression and vascular complications, based on integrated intraocular-plasma proteomics and multi-cohort validations.

Cardiology news

Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial

By MedXY 06/20/2026

This study reveals that sudden death in heart failure patients often follows gradual clinical decline, challenging the notion that such deaths are always abrupt.

Neurology news Pathology & Lab Medicine/Bệnh học

New Genetic Modifiers in Autosomal Dominant Alzheimer’s Disease Link Aβ, Tau, TDP-43, and Vascular Biology to Clinical Variability

By MedXY 06/03/2026

A genome-wide association study identified CNIH4, CCNG1, and RHOJ as genetic modifiers of autosomal dominant Alzheimer’s disease, with associations spanning disease risk, age at onset, fluid biomarkers, and neuroimaging phenotypes.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Elevated Von Willebrand Factor and Factor VIII Show Promise as Biomarkers for Diagnosis and Monitoring of Chronic Graft-Versus-Host Disease

By MedXY 05/27/2026

In a prospective cohort, VWF and FVIII were significantly elevated in chronic graft-versus-host disease, tracked with disease activity, and showed moderate diagnostic performance for early cGvHD.

Cardiology Clinical Updates news

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation

By MedXY 05/15/2026

This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality in patients with atrial fibrillation.

Cardiology news Pathology & Lab Medicine/Bệnh học

Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury

By MedXY 05/12/2026

A large multicohort and experimental study suggests the cTnI/cTnT ratio is biologically informative, separates acute from chronic myocardial injury, and modestly improves type 1 versus type 2 MI discrimination.

Critical Care news Respiratory

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

By MedXY 05/05/2026

AHRF patients classified as hypoinflammatory are not prognostically uniform. Continuous biomarker-based probabilities reveal substantial mortality heterogeneity, especially below the binary 0.5 threshold, with implications for enrichment strategies in phenotype-guided critical care trials.

$Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus$

Critical Care Neurology news

Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus

By MedXY 04/30/2026

In a multinational cross-sectional study, serum and CSF neurofilament light chain—unlike S100B—tracked severe acute brain injury in cryptogenic NORSE, rose rapidly over the first 3 weeks, and predicted poor short-term outcome, supporting urgent neuroprotective treatment.

Neurology news Pathology & Lab Medicine

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

By MedXY 04/28/2026

Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.

Critical Care Infectious Diseases news

Biomarker Signatures in Sepsis: Linking Host Response to Clinical Outcomes

By MedXY 04/28/2026

A prospective cohort study identifies biomarker signatures for host resistance, disease tolerance, and damage in sepsis, revealing associations with mortality and sepsis subtypes.

Cardiology news Oncology

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients

By MedXY 04/22/2026

Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.

Clinical Updates Neurology news Pathology & Lab Medicine

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

By MedXY 04/07/2026

This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cognitive decline.

Gastroenterology news Oncology

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

By MedXY 04/06/2026

A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease progression and mortality risk.